The MEK inhibitor trametinib has demonstrated beneficial effects in children with RASopathy-associated HCM, including improvements in cardiac hypertrophy, lower incidence of surgical intervention for LVOT obstruction and heart transplantation, and decreased mortality [40]. This evidence concerns the gene MAP2K7 and RASopathy.